Actively Recruiting
Registry and Biobank for Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases Studying Clinical and Biological Features to Improve Treatment and Understanding
Led by McGill University Health Centre/Research Institute of the McGill University Health Centre · Updated on 2021-09-09
252
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Systemic autoimmune rheumatic diseases SARDs, such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and autoimmune myositis, involve immune system dysregulation that can lead to lung damage known as interstitial lung disease ILD. This research aims to better understand the clinical, pathological, laboratory, and imaging features of SARD patients with lung involvement to identify unique characteristics and discover new disease mechanisms and potential treatment targets. The study will also address important clinical questions about predicting ILD development, disease progression, and treatment options in SARD patients. The study involves creating a longitudinal registry and biorepository of patients diagnosed with ILD-SARDs. Participants will provide clinical data, including medical history, imaging, pulmonary function tests, and treatment details, collected at every visit. Biological samples such as blood, serum, DNARNA, and excess biopsy tissues skin, lung, muscle, bronchoalveolar lavage will be collected and stored for future research. Blood samples from treatment-naive patients will be used for advanced genetic and immune cell analysis, and samples from others will be processed and biobanked. This setup supports future studies on disease mechanisms and potential therapies. Participants will be regularly assessed through clinical evaluations, questionnaires on symptoms and quality of life, and routine tests. The study will monitor outcomes like survival, lung transplant rates, acute exacerbations, hospitalizations, and patient-reported measures over five years. Medical oversight includes physical exams, adverse event monitoring, and laboratory result reviews. The research enables national and international collaboration to improve understanding and management of ILD in SARD patients, with an expected study duration extending to 2026.
CONDITIONS
Brief Title
ILD-SARDs Registry and Biorepository
Research Team
D
Deborah Assayag, MD, MAS
V
Victoria Nam-Amnath, RN, BScN
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
